Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023)

Organon & Co. Common Stock -2.83%

Organon & Co. Common Stock

OGN

15.12

-2.83%

Organon (NYSE:OGN) Third Quarter 2024 Results

Key Financial Results

  • Revenue: US$1.58b (up 4.1% from 3Q 2023).
  • Net income: US$359.0m (up by US$301.0m from 3Q 2023).
  • Profit margin: 23% (up from 3.8% in 3Q 2023). The increase in margin was primarily driven by lower expenses.
  • EPS: US$1.39 (up from US$0.23 in 3Q 2023).
earnings-and-revenue-growth
NYSE:OGN Earnings and Revenue Growth November 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Organon Earnings Insights

Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 10% growth forecast for the Pharmaceuticals industry in the US.

The company's shares are up 9.4% from a week ago.

Risk Analysis

Be aware that Organon is showing 3 warning signs in our investment analysis and 2 of those are concerning...

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via